{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:30:15Z","timestamp":1786437015056,"version":"build-2736575974"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To synthesise current international guidance on lutetium\u2010177\u2010labelled prostate\u2010specific membrane antigen (\n                      <jats:sup>177<\/jats:sup>\n                      Lu\u2010PSMA) radioligand therapy (RLT) across the prostate cancer disease spectrum, with emphasis on metastatic castration\u2010resistant prostate cancer (mCRPC) and emerging earlier\u2010line indications.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A structured literature overview was conducted. PubMed, EMBASE, and official repositories of major urological, oncological, and nuclear medicine societies were searched from inception to 31 October 2025 for prostate cancer guidelines. National and international guidelines or consensus statements published in English were eligible if they provided explicit recommendations regarding\n                      <jats:sup>177<\/jats:sup>\n                      Lu\u2010PSMA\u2010RLT in their most recent version. Documents without therapeutic recommendations or superseded by updated versions were excluded. Six major society guidelines were included: European Association of Urology (EAU 2025), American Urological Association\/Society of Urologic Oncology (AUA\/SUO 2023), National Comprehensive Cancer Network (NCCN 2025), Canadian Urological Association (CUA 2024), American Society of Clinical Oncology (ASCO 2025), and European Society for Medical Oncology (ESMO 2020). The joint European Association of Nuclear Medicine\/Society of Nuclear Medicine and Molecular Imaging (EANM\/SNMMI 2023) procedural guideline and expert consensus from the Advanced Prostate Cancer Consensus Conference (APCCC 2024) were also reviewed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All societies except ESMO, which has not yet updated its guidance on PSMA\u2010RLT, endorse\n                      <jats:sup>177<\/jats:sup>\n                      Lu\u2010PSMA\u2010617 for PSMA\u2010positive mCRPC following prior androgen receptor pathway inhibitor (ARPI) and taxane chemotherapy, supported by Level 1 evidence from the VISION and TheraP trials. Following PSMAfore, NCCN version1.2025, and more cautiously the EAU 2025 guideline, acknowledge expansion into taxane\u2010na\u00efve patients progressing after ARPI therapy. The recommended regimen remains 7.4\u2009GBq every 6\u2009weeks for up to six cycles with concurrent androgen deprivation therapy and multidisciplinary oversight.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>International guidelines largely converge on patient selection, dosing, and multidisciplinary implementation of PSMA\u2010RLT. Ongoing trials including PSMAfore, PSMAddition, UpFrontPSMA, ENZA\u2010p, and LuTectomy are expected to further define its role in earlier and combination treatment settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.70283","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:02:47Z","timestamp":1776168167000},"page":"359-369","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Guideline of guidelines: lutetium\u2010177\n                    <scp>PSMA<\/scp>\n                    radioligand therapy in advanced prostate cancer"],"prefix":"10.1111","volume":"138","author":[{"given":"Abdullah","family":"Al\u2010Khanaty","sequence":"first","affiliation":[{"name":"Division of Cancer Surgery Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Department of Surgery, Austin Health University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Department of Surgery, Austin Health University of Melbourne  Melbourne Victoria Australia"},{"name":"Department of Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Department of Medical Oncology Peter MacCallum Cancer Centre  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9086-8205","authenticated-orcid":false,"given":"Jonathan","family":"Walbaum","sequence":"additional","affiliation":[{"name":"Department of Urology Pontificia Universidad Cat\u00f3lica de Chile  Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hennes","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Hudson Institute of Medical Research Monash University  Clayton Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Delgado","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery Peter MacCallum Cancer Centre  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin","family":"Dinneen","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery Peter MacCallum Cancer Centre  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Eapen","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Department of Surgery, Austin Health University of Melbourne  Melbourne Victoria Australia"},{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8622-159X","authenticated-orcid":false,"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7350-5622","authenticated-orcid":false,"given":"Arun A.","family":"Azad","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Melbourne Victoria Australia"},{"name":"Department of Medical Oncology Peter MacCallum Cancer Centre  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7500-5899","authenticated-orcid":false,"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Department of Surgery Royal Melbourne Hospital, University of Melbourne  Melbourne Victoria Australia"},{"name":"EJ Whitten Prostate Cancer Research Centre at Epworth  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon","family":"Perera","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Department of Surgery, Austin Health University of Melbourne  Melbourne Victoria Australia"},{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267730"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269215"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00529-6"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00440-6"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5116"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","unstructured":"TagawaST.ESMO 2025: Phase III Trial of [177Lu]Lu\u2010PSMA\u2010617 combined with ADT + ARPI in patients with PSMA\u2010positive metastatic hormone\u2010sensitive prostate cancer (PSMAddition).","DOI":"10.1016\/j.annonc.2025.09.101"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00009-9"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.5005"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00559-5"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179755"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05392-2"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2023.1218670"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00672-1"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.09.017"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236414"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00135-9"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15101292"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06255-8"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268363"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.263996"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.22465\/juo.244600200010"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2024.10.084"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph18081215"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270889"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-024-00891-0"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04612-0"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.08.026"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70283","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bju.70283","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:01:29Z","timestamp":1786435289000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.70283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/bju.70283"],"URL":"https:\/\/doi.org\/10.1111\/bju.70283","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"2026-04-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}